PeterGRoseMD

Clinical Trials

• Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer Start of enrollment: 1993 Jun 01

  Terminated

  Phase 2

• Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Start of enrollment: 1994 Jun 01

  Completed

  Phase 3

• Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 1998 May 01

  Terminated

  Phase 1

• Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 1999 Mar 01

  Completed

  Phase 1

• Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 1999 Sep 01

  Completed

  Phase 1

• Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer Start of enrollment: 1998 Jun 01

  Terminated

  Phase 2

• Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20

  Completed

  Phase 2

• Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix Start of enrollment: 2001 Dec 01

  Terminated

  Phase 2

• Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Start of enrollment: 2007 Sep 01

  Completed

  Phase 1

• Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Start of enrollment: 2003 Oct 01

  Completed

  Phase 1

• Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Start of enrollment: 2005 Jan 01

  Completed

  Phase 1

• Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21

  Active, not recruiting

  Phase 3

• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06

  Active, not recruiting

  Phase 3

• Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01

  Completed

  Phase 2

• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18

  Recruiting

  Phase 3

• Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer Start of enrollment: 2008 Jul 01

  Completed

  Not Applicable

• Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01

  Completed

  Phase 3

• Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer Start of enrollment: 2007 Dec 01

  Completed

  Phase 2

• Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13

  Completed

  Phase 2

• Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01

  Completed

• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01

  Terminated

• Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Start of enrollment: 2009 Jul 01

  Completed

  Phase 2

• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29

  Active, not recruiting

  Phase 3

• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17

  Active, not recruiting

  Phase 3

• Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19

  Active, not recruiting

  Not Applicable

• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14

  Active, not recruiting

  Phase 2

• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28

  Completed

  Phase 1

• Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01

  Terminated

  Phase 3

• Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08

  Active, not recruiting

  Phase 2

• Ovarian Cancer Vaccine for Patients in Remission Start of enrollment: 2010 Jul 01

  Completed

  Phase 2

• Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01

  Completed

• Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12

  Active, not recruiting

  Phase 3

• Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12

  Active, not recruiting

  Phase 3

• Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07

  Completed

• Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01

  Completed

  Phase 2

• Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2011 Jun 06

  Completed

  Phase 2

• Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01

  Completed

  Phase 2

• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2011 Oct 01

  Completed

  Phase 2

• Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14

  Completed

  Phase 1

• Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer Start of enrollment: 2011 Apr 04

  Active, not recruiting

  Phase 1

• Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21

  Completed

  Phase 2

• Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09

  Completed

  Phase 3

• Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18

  Completed

  Phase 3

• Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02

  Active, not recruiting

  Phase 2

• Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Start of enrollment: 2012 Oct 01

  Completed

  Phase 1

• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30

  Completed

  Phase 1

• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14

  Terminated

  Phase 2

• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17

  Active, not recruiting

  Phase 2, Phase 3

• Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0 Start of enrollment: 2016 Apr 20

  Terminated

  Phase 2

• Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol Start of enrollment: 2020 Jan 15

  Recruiting

  Phase 1

• Join now to see all